m+Medelevator.RU
← Поиск публикаций
Innovation (Cambridge (Mass.)) · 2026

Organ-on-a-chip toxicology.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Yang Sheng, Zhang Tianyi, Ge Yiling, Niu Yiru, Chen Meng, Yin Lihong, Pu Yuepu, Chen Zaozao, Gu Zhongze, Liang Geyu

Аннотация

Traditional toxicology, with its reliance on animal models and oversimplified cell cultures, often fails to predict human responses due to interspecies differences and limited physiological relevance. Organ-on-a-chip (OoC) technology, as a microengineering breakthrough, enables reconstruction of human-relevant organ functions, providing a powerful tool for toxicity testing. However, OoC remains largely regarded as a technological platform rather than a distinct research discipline. In this review, we propose organ-on-a-chip toxicology (OCT) as a groundbreaking interdisciplinary paradigm that integrates advanced engineering, toxicological science, and biomedical research to redefine toxicological assessment. OCT transcends conventional OoC technology by providing a unified framework for elucidating toxicity effects and mechanisms at molecular, cellular, and organ levels. It uniquely enables comprehensive systemic toxicity modeling, incorporating full absorption-distribution-metabolism-excretion pathways and inter-organ signaling. Leveraging cutting-edge bioengineering, organoid-driven cellular fidelity, and AI-enhanced data analytics, OCT delivers unparalleled precision in drug safety evaluation, personalized toxicology, environmental hazard assessment, and food health. Despite current challenges in standardization, scalability, and regulatory acceptance, OCT holds the potential to revolutionize toxicological science by offering predictive, ethical, and human-centric insights, minimizing animal testing while advancing global health risk assessments.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты